172 related articles for article (PubMed ID: 10617866)
1. Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 prostate cancer models in nude mice.
El Etreby MF; Liang Y; Johnson MH; Lewis RW
Prostate; 2000 Feb; 42(2):99-106. PubMed ID: 10617866
[TBL] [Abstract][Full Text] [Related]
2. Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture.
El Etreby MF; Liang Y; Lewis RW
Prostate; 2000 Apr; 43(1):31-42. PubMed ID: 10725863
[TBL] [Abstract][Full Text] [Related]
3. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
[TBL] [Abstract][Full Text] [Related]
4. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells.
Wu HC; Hsieh JT; Gleave ME; Brown NM; Pathak S; Chung LW
Int J Cancer; 1994 May; 57(3):406-12. PubMed ID: 8169003
[TBL] [Abstract][Full Text] [Related]
5. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.
Thalmann GN; Sikes RA; Wu TT; Degeorges A; Chang SM; Ozen M; Pathak S; Chung LW
Prostate; 2000 Jul; 44(2):91-103 Jul 1;44(2). PubMed ID: 10881018
[TBL] [Abstract][Full Text] [Related]
6. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
7. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
8. Growth inhibition of androgen-insensitive human prostate carcinoma cells by a 19-norsteroid derivative agent, mifepristone.
Lin MF; Kawachi MH; Stallcup MR; Grunberg SM; Lin FF
Prostate; 1995 Apr; 26(4):194-204. PubMed ID: 7716084
[TBL] [Abstract][Full Text] [Related]
9. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
10. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride.
Umekita Y; Hiipakka RA; Kokontis JM; Liao S
Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11802-7. PubMed ID: 8876218
[TBL] [Abstract][Full Text] [Related]
11. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model.
Tuxhorn JA; McAlhany SJ; Dang TD; Ayala GE; Rowley DR
Cancer Res; 2002 Jun; 62(11):3298-307. PubMed ID: 12036948
[TBL] [Abstract][Full Text] [Related]
12. Mifepristone-induced secretion of transforming growth factor beta1-induced apoptosis in prostate cancer cells.
Liang Y; Eid MA; El Etreby F; Lewis RW; Kumar MV
Int J Oncol; 2002 Dec; 21(6):1259-67. PubMed ID: 12429976
[TBL] [Abstract][Full Text] [Related]
13. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
14. Growth of an androgen-sensitive human prostate cancer cell line, LNCaP, in nude mice.
Lim DJ; Liu XL; Sutkowski DM; Braun EJ; Lee C; Kozlowski JM
Prostate; 1993; 22(2):109-18. PubMed ID: 7681204
[TBL] [Abstract][Full Text] [Related]
15. Human prostate tumor angiogenesis in nude mice: metalloprotease and plasminogen activator activities during tumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate tumor cells.
Wilson MJ; Sinha AA
Anat Rec; 1997 Sep; 249(1):63-73. PubMed ID: 9294650
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
17. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines.
Wu TT; Sikes RA; Cui Q; Thalmann GN; Kao C; Murphy CF; Yang H; Zhau HE; Balian G; Chung LW
Int J Cancer; 1998 Sep; 77(6):887-94. PubMed ID: 9714059
[TBL] [Abstract][Full Text] [Related]
18. Variants of the human prostate LNCaP cell line as tools to study discrete components of the androgen-mediated proliferative response.
Soto AM; Lin TM; Sakabe K; Olea N; Damassa DA; Sonnenschein C
Oncol Res; 1995; 7(10-11):545-58. PubMed ID: 8866667
[TBL] [Abstract][Full Text] [Related]
19. Mifepristone inhibits GRĪ² coupled prostate cancer cell proliferation.
Ligr M; Li Y; Logan SK; Taneja S; Melamed J; Lepor H; Garabedian MJ; Lee P
J Urol; 2012 Sep; 188(3):981-8. PubMed ID: 22819113
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of caspases by cytokine response modifier A blocks androgen ablation-mediated prostate cancer cell death in vivo.
Srikanth S; Kraft AS
Cancer Res; 1998 Feb; 58(4):834-9. PubMed ID: 9485043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
